fbpx

Excerpts from the publication

Background
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma.

Methods
After psychiatric medication washout, participants (n = 90) were randomized 1:1 to receive manualized therapy with MDMA or with placebo, combined with three preparatory and nine integrative therapy sessions. PTSD symptoms, measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5, the primary endpoint), and functional impairment, measured with the Sheehan Disability Scale (SDS, the secondary endpoint) were assessed at baseline and at 2 months after the last experimental session. Adverse events and suicidality were tracked throughout the study.

Results
MDMA was found to induce significant and robust attenuation in CAPS-5 score compared with placebo (P < 0.0001, d = 0.91) and to significantly decrease the SDS total score (P = 0.0116, d = 0.43). The mean change in CAPS-5 scores in participants completing treatment was −24.4 (s.d. 11.6) in the MDMA group and −13.9 (s.d. 11.5) in the placebo group. MDMA did not induce adverse events of abuse potential, suicidality or QT prolongation. Conclusions These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities. We conclude that MDMA-assisted therapy represents a potential breakthrough treatment that merits expedited clinical evaluation.

Read more

Psychedelic-Assisted Group Therapy: A Systematic Review

Alexander Trope, Brian T. Anderson, Andrew R. Hooker, Giancarlo Glick, Christopher Stauffer, Joshua D. Woolley
April 2019

A new approach methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity in humans

Miaoying Shi, Sebastiaan Wesseling, Hans Bouwmeester and Ivonne M. C. M. Rietjens
July 2021

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health

Sam Gandy, Matthias Forstmann, Robin Lester Carhart-Harris, Christopher Timmermann, David Luke, Rosalind Watts
December 2020

The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)

Johannes T. Reckweg, Malin V. Uthaug, Attila Szabo, Alan K. Davis, Rafael Lancelotta, Natasha L. Mason, Johannes G. Ramaekers
February 2022